EU reality: authorization and conditions of use control the label vocabulary

The EU approach is strict in a practical way. If a label communicates a relationship between a food and health, regulators can treat it as a health claim.
Regulation (EC) No 1924/2006 sets the framework for nutrition and health claims.
It also links “allowed wording” to scientific evaluation and to conditions of use.
This structure means that a brand cannot assume that a friendly sentence is “fine” because it sounds mild.
The key question is whether the claim falls into a regulated category and whether it is used in the authorized way.
The EU Register exists as a reference for what is authorized, what is not authorized, and what conditions apply.
A gut-tea label becomes fragile when it relies on broad health effects without a permitted wording path.

US reality: claim category and implied meaning determine risk

In the US, FDA explains three core categories used on labels: health claims, nutrient content claims, and structure/function claims.
FDA also explains that it is likely to interpret the dividing line between structure/function claims and disease claims in a similar manner for conventional foods as for dietary supplements.
This matters because gut teas often use phrases that can imply treatment.
Words like “cures,” “relieves,” “heals,” and “fixes” often signal disease or condition treatment.
Even without those words, a claim can still imply treatment if it targets a diagnosed condition or promises a medical outcome.
A label stays safer when it focuses on normal function, comfort, and everyday experience, and when it avoids condition naming.

Phrase	Why buyers love it	Why regulators may not	EU risk	US risk	Defensible rewrite
“Treats constipation”	It promises a clear outcome	It reads like a medicinal claim	High	High	“Supports regularity when used as directed” (with clear boundaries)
“Relieves IBS”	It targets a known pain point	It names a condition and implies treatment	High	High	“Supports digestive comfort” (avoid conditions and absolutes)
“Heals your gut”	It sounds powerful	It implies medical repair	High	High	“Formulated for post-meal comfort” (pair with usage guidance)
“Cleanses your colon”	It signals a strong “clean” effect	It implies a medical process and can suggest a risky action	High	High	“Occasional-use herbal blend” (with clear warnings if laxative botanicals exist)
“Supports digestion”	It feels gentle and broad	It can still be interpreted as a health claim depending on context	Medium	Medium	“Supports normal digestive comfort” (add serving + boundaries)

Evidence (Source + Year):

• European Parliament and Council, Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, 2006.
• U.S. Food and Drug Administration (FDA), “Label Claims for Conventional Foods and Dietary Supplements” and “Structure/Function Claims,” 2024.

A simple “normal function” vocabulary bank keeps language out of treatment territory

Defensible gut-tea copy usually starts with the consumer’s everyday experience. A label can describe “comfort,” “post-meal heaviness,” “gentle support,” or “regularity support.”
Each of these phrases still needs careful use, but they are closer to normal function than to treatment.
Treatment verbs like “cure,” “relieve,” “fix,” and “heal” often change the legal and consumer interpretation in one step.
The label also needs modesty. “Works overnight” and “guaranteed results” invite scrutiny because they sound like drug outcomes.
A brand can replace absolutes with boundaries and conditions.
A label can say “for occasional use,” “use as directed,” and “not intended for continuous daily use,” when that aligns with the formula and the risk profile.
This structure helps because it forces the brand to define what is actually being promised.

Verification cues do not replace compliance, but they reduce dispute friction

A gut-tea label often faces two types of disputes. One dispute is about whether the product works. Another dispute is about whether the product was formulated and controlled as promised.
Verification cues help with the second dispute.
A lot code, a batch identifier, and a QR link to a real document set can reduce buyer anxiety.
This matters for international buyers who cannot visit the facility and who rely on paperwork.
FTC’s substantiation principle focuses on having a reasonable basis for objective claims before marketing.
A label that is supported by a stored proof file is easier to defend than a label that relies on story language.
FDA’s structure/function explanations also highlight why claim category and implied meaning matter.
A verification path supports a disciplined internal process, and disciplined processes help claims stay stable after scale.

Claim goal	Risky copy	Defensible copy	What must be true operationally	What proof to store
Post-meal comfort	“Stops bloating”	“Supports digestive comfort after meals”	Formula avoids drug-like actives and is consistent	Ingredient identity + blend spec + complaint review log
Occasional regularity	“Flushes your system”	“Occasional-use herbal blend; use as directed”	Clear use instructions and warning set match ingredient risk	Warning rationale + usage directions + retention samples
“Gentle” positioning	“Gentle detox”	“Caffeine-free herbal blend; transparent ingredients”	Ingredient list supports “gentle” meaning	COAs + allergen/cross-contact controls
Trust through transparency	“Clinically proven” (without details)	“Batch COA via QR” (if true)	QR links to real COAs by lot, not marketing pages	COA archive + lot mapping + version control

Evidence (Source + Year):

• Federal Trade Commission (FTC), “FTC Policy Statement Regarding Advertising Substantiation” (appended to Thompson Medical Co., 104 F.T.C. 648), 1984.
• U.S. Food and Drug Administration (FDA), “Structure/Function Claims,” 2024.

Comfort botanicals behave like everyday beverages, but they still need boundaries

Comfort botanicals often include ginger, peppermint, fennel, chamomile, lemon balm, and similar ingredients.
These blends usually aim for a mild consumer experience.
The label can focus on sensory and routine positioning, such as “after-meal comfort,” “warming spice notes,” or “evening-friendly herbal blend.”
The claim still needs a basis and serving logic. A label also needs to avoid turning a mild blend into a medical promise.
A brand can add boundaries such as “for routine enjoyment” and “not intended to diagnose, treat, cure, or prevent any disease” where relevant for the market and category.
The label can also reduce risk by keeping claims modest and by avoiding condition names.

Stimulant laxative botanicals change the warning burden and change the buyer expectation

Stimulant laxative botanicals such as senna create a different consumer outcome profile.
Consumers can experience cramps, diarrhea, dehydration, and electrolyte issues when use is excessive or when users are sensitive.
This is why many herbal medicinal references include contraindications and duration limits for senna.
A label that uses stimulant laxatives should not hide behind “gentle cleanse” language.
It should clearly signal occasional use, direction limits, and who should not use the product.
The label can also reduce claims and focus more on usage directions and warnings, because strong effect language increases both risk and complaint volume.

“Probiotic/prebiotic” terms and botanical-claim uncertainty can create EU-specific fragility

Many gut-positioned beverages want to borrow microbiome language.
In the EU, the term “probiotic” has been described by EU-facing sources as an unauthorized health claim in many contexts, because it implies a health benefit.
That means a label can become non-defensible if it relies on that word without an authorized claim path.
Separately, EFSA has maintained “on-hold” botanical claim materials for years.
This creates uncertainty for botanical claims that sound like health effects.
Conservative phrasing can protect listings when the claim landscape is uncertain.
A safer approach is to describe ingredients factually and avoid implying outcomes that trigger a regulated claim category.

Ingredient family	Typical consumer expectation	Allowed/defensible label direction	Common compliance trap	Safer positioning
Comfort botanicals	Mild relief, soothing routine	Normal-function comfort language + serving clarity	Condition claims (“gastritis,” “IBS,” “GERD”)	“Post-meal comfort,” “herbal blend,” “caffeine-free”
Stimulant laxatives (e.g., senna)	Strong effect, quick result	Occasional-use framing + strict directions + warnings	Calling it “gentle” while hiding stimulant actives	“Occasional use only,” “do not exceed,” contraindication set
“Biotic” language	Microbiome and gut balance promise	Market-specific wording and claim review	Using “probiotic” as a casual descriptor in EU contexts	List strains/ingredients factually and avoid implied health effects
Cleanse/flush framing	“Reset” and “toxins out” promise	Shift to measurable attributes and safe usage	Unfalsifiable “detox” claims that invite scrutiny	“Hydration support,” “ingredient transparency,” “occasion-based routine”

Evidence (Source + Year):

• European Parliament, “Use of the term ‘probiotic’ and nutrition claims” (E-004201/2017), 2017.
• European Food Safety Authority (EFSA), “Questions on hold: botanical claims submitted to EFSA” (updated July 2011 file), 2011.

Senna warning architecture: duration limits and who should not use

Senna is a clear example of why ingredient-driven warnings matter.
If a product contains senna, the label should treat it as a high-responsibility ingredient.
Herbal monographs and references often describe senna for short-term use for occasional constipation, and they list contraindications for children under a certain age and for pregnancy and breastfeeding.
They also highlight risks connected to dehydration and electrolyte imbalance when misuse occurs.
A label can translate this into practical retail language.
The label can state “for occasional use only,” “do not exceed the recommended serving,” and “do not use for extended periods.”
The label can also include “do not use if you have abdominal pain, intestinal obstruction, or inflammatory bowel conditions,” when that aligns with the relevant guidance and market advice.
This warning set reduces complaint rates because it sets realistic expectations and it discourages misuse.

Licorice warning architecture: glycyrrhizin risk and higher-risk populations

Licorice is often included in “soothing digestion” blends, but it is not a neutral ingredient for every user.
NCCIH has described that glycyrrhizin in licorice can cause serious adverse effects in certain contexts, especially with large amounts or long-term use.
NCCIH also notes that even small amounts have been linked to severe adverse effects in people with hypertension and in people with heart or kidney conditions, and it highlights the role of salt intake and other risk factors.
A practical label should warn higher-risk users in simple terms.
The label can warn people with high blood pressure, heart disease, or kidney disease to consult a health professional.
The label can also discourage long-term continuous daily use if the blend is positioned as a routine beverage.
This warning approach is not fear marketing. It is risk alignment.
It protects the brand and it protects the buyer from predictable misfit use cases.

Ingredient trigger	Core risk	Who is higher risk	Minimum warning text concept	What the brand must verify
Senna	Diarrhea, cramps, dehydration, electrolyte imbalance with misuse	Children, pregnant/breastfeeding users, users with GI disease	“Occasional use only. Do not exceed directions. Not for children. Consult a professional if pregnant or breastfeeding.”	Accurate ingredient ID and consistent dose per serving
Licorice root (glycyrrhizin)	Blood pressure and electrolyte effects in sensitive users	Hypertension, heart or kidney conditions, high salt intake	“Consult a professional if you have high blood pressure or heart/kidney conditions.”	Clear disclosure of licorice form and realistic use guidance
“Cleanse/flush” positioning	Misuse behavior and unrealistic expectation	Users who escalate dose or duration	“Not intended for continuous daily use. Use as directed.”	Consumer directions match actual formula risk
Multi-botanical blends	Interaction uncertainty and user confusion	Users on medications	“Consult a professional if you take medications or have a medical condition.”	Ingredient list accuracy and allergen control

Evidence (Source + Year):

• European Medicines Agency (EMA), “EU herbal monograph on senna leaf” (Sennae folium, Revision 1), 2018.
• National Center for Complementary and Integrative Health (NCCIH, NIH), “Licorice Root: Usefulness and Safety” (Last Updated: April 2025), 2025.

Evidence mapping rules: the proof must match the product format and the serving

A gut-tea defense file starts with a reality check.
A study on a concentrated extract does not automatically support a claim for a tea bag infusion.
A study at a high dose does not automatically support a claim at a lower serving.
A study in a different population does not automatically apply to the target consumer group.
Evidence mapping is a simple method. It matches each claim to the product’s format, dose, and intended use.
It also lists what the claim does not promise.
This approach reduces risk because it prevents over-reading of research.
It also helps the brand write modest copy that aligns with what is reasonably supported.
FTC’s substantiation principle focuses on having a reasonable basis for objective claims before marketing.
A well-structured mapping table is part of that reasonable basis because it shows the brand’s logic and controls.

Version control across markets: a strong claim system fails if artwork leaks across borders

International gut-tea brands often fail through operations, not through science.
A marketing team approves one sentence, then a distributor reuses it in another market, and the label becomes non-defensible.
A defense file should include version control rules.
It should list which claims are allowed in which markets.
It should list which warnings are mandatory for which ingredient sets.
It should also identify who owns the final sign-off.
FDA explains label-claim categories in a way that helps brands categorize their copy.
The EU framework adds authorization constraints and conditions of use.
A brand does not need to master every jurisdiction inside one PDF, but the brand needs a control system that prevents “one label for all” mistakes.

File component	Why it matters	“Pass” standard	“Fail” example	Owner
Ingredient identity + spec	Claims require consistent inputs	Supplier COA + internal spec range	Ingredient swaps without label updates	Brand + supplier
Serving-based rationale	Claims depend on serving and frequency	Defined serving size tied to label wording	Claim has no serving logic	Brand
Evidence mapping	Proof must match format and dose	Claim-to-evidence table with boundaries	One generic paper used for every claim	Brand + advisor
Warning rationale	Warnings reduce predictable harm and complaints	Ingredient-driven warning rules by formula type	Warnings added only after complaints	Brand
Artwork version control	Market mistakes break defensibility	Market-specific artwork IDs and approval workflow	Distributor edits copy without control	Brand + co-man
QR document archive (optional)	It reduces buyer friction when done correctly	Lot-based COA archive with stable links	QR links to marketing claims only	Brand

Evidence (Source + Year):

• Federal Trade Commission (FTC), “FTC Policy Statement Regarding Advertising Substantiation” (appended to Thompson Medical Co., 104 F.T.C. 648), 1984.
• U.S. Food and Drug Administration (FDA), “Label Claims for Conventional Foods and Dietary Supplements,” 2024.

JINYI is a source factory for flexible packaging. We aim to deliver reliable, user-friendly, and implementable packaging solutions to brands, enabling clients to achieve more consistent quality, clearer delivery times, and packaging structures and printing effects that better match their products with less communication costs.